We report the case of a 52-year-old man with AIDS and CMV bilateral retinitis, treated first with ganciclovir (cymevan) and then with cidofovir. During the treatment, the patient complained of a sharp decrease in visual acuity. Cycloplegics and topical corticosteroids were given. Then cidofovir was stopped and replaced with intravenous Foscavir because of the clinical inefficacy. The anterior uveitis resolved but the ciliary secretion has not stopped after 12 months of follow-up. The patient presented +11 hypermetropia with a choroidal edema and bilateral cataract. This case is interesting for its permanent hypotony and bilateral uveitis. A literature search has brought out a rate of only 3% of chronic hypotony. We hypothesize bilateral iatrogenic ciliary body necrosis, as described in the animal models.
Download full-text PDF |
Source |
---|
Ocul Immunol Inflamm
January 2025
Division of Ocular Immunology, Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Purpose: To assess the patient barriers to adherence with appointment follow-up in patients with ocular inflammatory disorders across the United States.
Methods: This was a multicenter study of adult and pediatric patients at the Wilmer Eye Institute, University of Texas at Austin, University of Wisconsin-Madison, University of Minnesota, Minneapolis Veterans Administration Hospital, and Washington University of St. Louis.
JAMA Ophthalmol
January 2025
Department of Cornea and Refractive Surgery, Narayana Nethralaya, Bangalore, India.
Eye (Lond)
January 2025
College of pharmacy, Changsha Medical University, Changsha, China.
Background: Uveitis is a rare ocular adverse reaction of zoledronic acid, the specific clinical features are not clarified. This study was to investigate the clinical features of zoledronic acid-induced uveitis and provide reference for rational use of zoledronic acid.
Methods: We collected clinical data on zoledronic acid-induced uveitis for retrospective analysis by searching Chinese and English data up to October 31, 2024.
Graefes Arch Clin Exp Ophthalmol
January 2025
15-20 National Ophthalmologic Center, Paris, France.
Purpose: Intravitreal injections of anti-VEGF agents are considered as safe, with a very low rate of intraocular inflammations (IOI). Faricimab is a novel intravitreal bispecific antibody targeting both VEGF-A and angiopoietin-Tie2 independently. Despite a safe profile in randomized clinical trials, several real-life studies have reported cases of IOI.
View Article and Find Full Text PDFOcul Immunol Inflamm
January 2025
Ophthalmology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Purpose: To describe a case series of presumed Sympathetic Ophthalmia (SO) triggered by diode laser cyclophotocoagulation (CPC) for the treatment of neovascular glaucoma.
Methods: Patients developing bilateral granulomatous uveitis after CPC between 2014 and 2024. Cases with prior ocular trauma or penetrating ocular surgery were excluded.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!